[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363630-105":59,"doc-detail-363630-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-prognostic-significance-of-prostate-specific-antigen-dynamics-during-abiraterone-therapy-inpatients-with-high-risk-metastatic-hormone-sensitive-prostate-cancer","The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy inpatients with high-risk metastatic hormone-sensitive prostate cancer","","Evaluate prognostic value of prostate-specific antigen (PSA) decline depth and duration in high-risk metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with first-line abiraterone. Retrospective analysis of 153 high-risk inpatients stratified by PSA dynamics used Kaplan–Meier and Cox models to link PSA decline patterns with PSA progression-free survival (PSA-PFS), radiographic PFS (rPFS), and overall survival (OS). PSA nadir thresholds (\u003C0.2, 0.2–\u003C4, ≥4 ng mL−1) and sustained PSA \u003C0.2 within 6 months for >10 months independently predicted improved outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-prognostic-significance-of-prostate-specific-antigen-dynamics-during-abiraterone-therapy-inpatients-with-high-risk-metastatic-hormone-sensitive-prostate-cancer/363630/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-prognostic-significance-of-prostate-specific-antigen-dynamics-during-abiraterone-therapy-inpatients-with-high-risk-metastatic-hormone-sensitive-prostate-cancer/363630.png","ImageObject",300,407,{"name":92,"@type":93},"Kurz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the study’s main goal?","Question",{"text":113,"@type":114},"To evaluate how PSA decline depth and PSA decline duration during abiraterone treatment relate to prognosis in high-risk metastatic hormone-sensitive prostate cancer patients.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were patients grouped for analysis?",{"text":118,"@type":114},"Patients were retrospectively stratified based on PSA dynamics during treatment, including PSA nadir thresholds (\u003C0.2 ng mL−1, 0.2 to \u003C4 ng mL−1, and >4 ng mL−1).",{"name":120,"@type":111,"acceptedAnswer":121},"Which PSA decline pattern was associated with better survival outcomes?",{"text":122,"@type":114},"Achieving PSA \u003C0.2 ng mL−1 within 6 months and maintaining this level for over 10 months was linked to significantly improved PSA-PFS, rPFS, and OS, and was identified as an independent prognostic factor.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},363630,1790381197,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Asian Journal of Andrology (2026) 28, 304–309 [www.asiaandro.com](www.asiaandro.com); [https://journals.lww.com/ajandrology](https://journals.lww.com/ajandrology)  \nOpen Access  \nProstate Cancer  \nORIGINAL ARTICLE  \nThe prognostic significance of prostate-specific antigen dynamics during abiraterone therapy inpatients with high-risk metastatic hormone-sensitive prostate cancer  \nQian Wang*, Ming Zhang*, Qi-Yu Zhu, Hong Zeng, Jin-Dong Dai, Ke Huang, Si-Cheng Wan, Yi-Fu Shi, Xing-Ming Zhang, Hao Zeng, Peng-Fei Shen  \nTo evaluate the prognostic significance of prostate-specific antigen (PSA) decline depth and duration in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) undergoing abiraterone treatment. We retrospectively analyzed data from 153 high-risk patients with mHSPC receiving first-line abiraterone therapy. Patients were stratified based on PSA dynamics during treatment. Kaplan–Meier survival analysis and Cox proportional hazards regression were used to assess the associations between PSA decline patterns, PSA progression-free survival (PSA-PFS), radiographic PFS (rPFS), and overall survival (OS) . Among the 153 patients, 85 exhibited PSA nadir \u003C0.2 ng ml−1, 48 had PSA nadir level ranging from 0.2 ng ml−1 to 4 ng ml−1, and 20 presented with a PSA nadir >4 ng ml−1 . During abiraterone treatment, PSA nadir \u003C0.2 ng ml−1 was significantly associated with improved median PSA-PFS (51.0 months vs 18.5 months vs 6.9 months, P \u003C 0 .0001), median rPFS (52 .0 months vs 24.3 months vs 10.3 months, P \u003C 0 .0001), and median OS (not reached vs 48.5 months vs 28.1 months, P \u003C 0.0001) compared with PSA nadir ≥0.2 ng ml-1 and \u003C4 ng ml-1, and PSA nadir ≥4 ng ml-1. In the cohort with PSA nadir \u003C0.2 ng ml−1, achieving PSA \u003C0.2 ng ml−1 within 6 months and maintaining this level for over 10 months significantly enhanced clinical outcomes, as evidenced by median PSA-PFS (not reached vs 26.9 months, P \u003C 0.0001), median rPFS (not reached vs 27.5 months, P \u003C 0.0001), and median OS (not reached vs 44.4 months, P \u003C 0.0001) . Cox regression analysis revealed that achieving PSA \u003C0.2 ng ml−1 within 6 months post-treatment and sustaining this level for over 10 months are independent prognostic factors. In high-risk patients with mHSPC receiving first-line abiraterone, sustained PSA suppression is a key indicator of therapeutic response. The rate, depth, and duration of PSA decline are critical prognostic factors.  \nAsian Journal of Andrology (2026) 28 , 304–309; doi: 10.4103/aja202520; published online: 09 January 2026 Keywords: dynamics; high-risk; prognostic; prostate cancer; PSA  \nINTRODUCTION  \nProstate cancer is among the most prevalent malignant tumors of the male genitourinary system. Globally, it ranks first in incidence and second in mortality among male malignancies, with both rates rising annually.1 Due to the absence of early screening, approximately 54% of patients are diagnosed at the metastatic hormone-sensitive prostate cancer (mHSPC) stage.2,3 Compared with localized disease, metastatic prostate cancer is associated with a twofold reduction in progression-free survival (PFS), and its 5-year relative survival rate declines from 80% to 30% .4,5 Advances in prostate cancer therapeutics and clinical trials have demonstrated the benefits of combining abiraterone or other novel endocrine therapies with androgen deprivation therapy (ADT) across various stages of mHSPC.6,7  \nThe LATITUDE study established the significant overall survival (OS) and PFS benefits of abiraterone in high-risk mHSPC.4 A  \nsubsequent analysis revealed that in 45% of abiraterone-treated patients, prostate-specific antigen (PSA) levels did not decline to an undetectable nadir (PSA \u003C0.2 ng ml−1), and these patients had significantly poorer survival outcomes.8 Additionally, previous studies have suggested that the depth of PSA decline and the hemoglobin-to-neutrophil ratio are effective predictors of survival in abiraterone-treated patients.9,10 P","cbCaiuyGyUtJV5qx","https://ap.wps.com/l/cbCaiuyGyUtJV5qx","pdf",1302329,"English","# Introduction\n# Patients and Methods\n## Study design\n# Results\n# Discussion\n# Conclusion","[{\"question\":\"What was the study’s main goal?\",\"answer\":\"To evaluate how PSA decline depth and PSA decline duration during abiraterone treatment relate to prognosis in high-risk metastatic hormone-sensitive prostate cancer patients.\"},{\"question\":\"How were patients grouped for analysis?\",\"answer\":\"Patients were retrospectively stratified based on PSA dynamics during treatment, including PSA nadir thresholds (\\u003c0.2 ng mL−1, 0.2 to \\u003c4 ng mL−1, and \\u003e4 ng mL−1).\"},{\"question\":\"Which PSA decline pattern was associated with better survival outcomes?\",\"answer\":\"Achieving PSA \\u003c0.2 ng mL−1 within 6 months and maintaining this level for over 10 months was linked to significantly improved PSA-PFS, rPFS, and OS, and was identified as an independent prognostic factor.\"}]","The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy inpatients with high-risk metastatic hormone-sensitive prostate cancer | PDF",1790152267,18,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3ab721055213d1f1ec7217c94332b8d.webp",983,1287,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a6ff41d316d78cd773b4091d5d55fac.webp",982,1286,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9dd8e5314d6439f6e3392f784a51fa76.webp",981,1284,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85e5ad89c83aab0d414ada6ac0c87d6f.webp",980,1283]